SCHEMBL1433488

SCHEMBL1433488

C=C(C)c1ccc(F)c(F)c1F

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.54
CES1 P23141 3/20 0.54
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31599525 1.00 CES2 (0.54) CES2CES1BCHE
SCHEMBL21262449 0.82 CES2 (0.40) CES2CES1BCHE
SCHEMBL8281293 0.82 CES2 (0.35) CES2CES1
SCHEMBL16956339 0.80 CES2 (0.58) CES2CES1BCHE
SCHEMBL14040983 0.79 CES2 (0.56) CES2CES1BCHE
SCHEMBL1808758 0.78 CES2 (0.56) CES2CES1BCHE
SCHEMBL22640332 0.77 CES2 (0.31) CES2CES1
SCHEMBL17128930 0.77 CA12 (0.43) CES2CES1
SCHEMBL671906 0.76 CES2 (0.67) CES2CES1BCHE
SCHEMBL29775631 0.76 CES2 (0.67) CES2CES1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 US disclosed
EP-4605388-A1 <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 Astrazeneca AB (SE) 2025-08-27 EP disclosed
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-11-21 US disclosed
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-06-20 US disclosed
WO-2024083933-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 ASTRAZENECA AB (SE) 2024-04-25 WO disclosed
EP-1893323-B1 A METHOD OF PREPARING A RADIATION FUEL CELL MEMBRANE WITH ENHANCED CHEMICAL STABILITY AND A MEMBRANE ELECTRODE ASSEMBLY SCHERRER INST PAUL (CH) 2011-03-30 EP disclosed
US-20080199754-A1 Method for Preparing a Radiation Grafted Fuel Cell Membrane with Enhanced Chemical Stability and a Membrane Electrode Assembly PAUL SCHERRER INSTITUT (CH) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 CES2 3829/4885CES1 4432/4885BCHE 4871/4885
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 CES2 3829/4885CES1 4432/4885BCHE 4871/4885
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 CES2 3829/4885CES1 4432/4885BCHE 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.